Drug intelligence / Profile preview

4P018

Development stage: Preclinical
Lead developer: 4P-Pharma
Modality: Small Molecules

Overview

4P018 (also known as 4P-018) is an early-stage drug candidate being developed by 4P-Pharma for the treatment of Alzheimer's disease. The therapeutic is currently in preclinical development, with 4P-Pharma utilizing its translational R&D platform to advance the asset toward clinical-stage evaluation.

Beyond the preview

Go deeper on 4P018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4P018.

Explore the full profile